MedTech Unboxed: Christopher Haig, President at Efemoral Medical
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
MedTech Unboxed: Christopher Haig, President at Efemoral Medical
-
Lu par :
-
De :
À propos de ce contenu audio
A new MedTech Unboxed episode is out now with Christopher Haig, President of Efemoral Medical, a company developing bioresorbable scaffolds for treating peripheral arterial disease (PAD), affecting over 200 million globally. Here’s a snapshot of our discussion:
- FlexStep Technology: A balloon-expandable, drug-eluting bioresorbable scaffold with inter-scaffold spaces for flexibility, made of PLLA with a co-polymer for ductility and rapid resorption (1-2 years), eluting sirolimus to prevent restenosis.
- Clinical Progress: The EFEMORAL I trial (33 patients enrolled across 4 sites in New Zealand/Australia) shows promise, with 20-patient results to be presented by Dr. Andrew Holden at @CXSymposium in London, April 23, 2025.
- Funding Update: Raised $10M+ in equity through angel investors and $2M+ in SBIR grants; targeting $20M Series B for IDE submission, including GLP animal studies and randomized trials for US PMA approval.
Aucun commentaire pour le moment